Astex and Otsuka Announce Results of the Phase 3 ASCERTAIN Study of the Novel Oral Cedazuridine/Decitabine Fixed-Dose Combination (ASTX727) in Patients with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

17

PLEASANTON, Calif. & TOKYO–(BUSINESS WIRE)–Astex & Otsuka announce that the phase 3 ASCERTAIN study of oral ASTX727 cedazuridine/decitabine in patients with MDS/CMML met the primary endpoint….

 

 

 

 

 

 

http://www.businesswire.com/news/home/20190606005862/en/Astex-Otsuka-Announce-Results-Phase-3-ASCERTAIN